Identification of rare variants in Alzheimer’s disease
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Much progress has been made in recent years in identifying genes involved in the risk of developing Alzheimer's disease (AD), the most common form of dementia. Yet despite the identification of over 20 disease associated loci, mainly through genome wide association studies (GWAS), a large proportion of the genetic component of the disorder remains unexplained. Recent evidence from the AD field, as with other complex diseases, suggests a large proportion of this "missing heritability" may be due to rare variants of moderate to large effect size, but the methodologies to detect such variants are still in their infancy. The latest studies in the field have been focused on the identification of coding variation associated with AD risk, through whole-exome or whole-genome sequencing. Such variants are expected to have larger effect sizes than GWAS loci, and are easier to functionally characterize, and develop cellular and animal models for. This review explores the issues involved in detecting rare variant associations in the context of AD, highlighting some successful approaches utilized to date.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Harold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326
Self-citationTargeted capture and massively parallel sequencing of 12 human exomes
Ng, S. B., Turner, E. H., Robertson, P. D., Flygare, S. D., Bigham, A. W., Lee, C., Shaffer, T., Wong, M., Bhattacharjee, A., Eichler, E. E., et al. (2009) · Nature · doi:10.1038/nature08250 · Cited by 2,030 · cited 1×
“Exome sequencing, although only targeting 1–2% of the genome, targets the most commonly disease associated regions (Ng et al., 2009).”
BackgroundInitiative, T. A. D. N., Hollingworth, P., CHARGE consortium, EADI1 consortium, Harold, D., Sims, R., Gerrish, A., Lambert, J.-C., Carrasquillo, M. M., Abraham, R., et al. (2011) · Nature Genetics · doi:10.1038/ng.803 · Cited by 1,997 · cited 2×
“Keywords: Alzheimer’s disease, rare variants, exome sequencing, genome sequencing, replication, population differences”
BackgroundInfluentialSelf-citationNaj, A. C., Jun, G., Beecham, G. W., Wang, L.-S., Vardarajan, B. N., Buros, J., Gallins, P. J., Buxbaum, J. D., Jarvik, G. P., Crane, P. K., et al. (2011) · Nature Genetics · doi:10.1038/ng.801 · Cited by 1,901 · cited 1×
“…then, through ever increasing sample sizes and meta-analyses, a further 17 genes have been reported to be associated with AD via GWAS, most recently in a “mega”meta-analyses featuring almost 75000 samples (Seshadri et al., 2010; Hollingworth et al., 2011; Naj et al., 2011; Lambert et al., 2013).”
BackgroundSelf-citationRole of Genes and Environments for Explaining Alzheimer Disease
Gatz, M., Reynolds, C. A., Fratiglioni, L., Johansson, B., Mortimer, J. A., Berg, S., Fiske, A., & Pedersen, N. L. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.2.168 · Cited by 1,798 · cited 2×
“Although the heritability of the disease is estimated to be around 60–80% (Gatz et al., 2006), our understanding of the genes and loci involved has been limited until relatively recently.”
BackgroundInfluentialA mutation in APP protects against Alzheimer’s disease and age-related cognitive decline
Jonsson, T., Atwal, J. K., Steinberg, S., Snaedal, J., Jonsson, P. V., Bjornsson, S., Stefansson, H., Sulem, P., Gudbjartsson, D., Maloney, J., et al. (2012) · Nature · doi:10.1038/nature11283 · Cited by 1,738 · cited 4×
“APP (PROTECTIVE) With APP as a clear biological candidate for involvement in AD risk, Jonsson et al. (2012) sought low frequency and rare mutations in whole genome sequence from 1795 Icelanders, and imputed recurrent variants in 71,743 chip-genotyped Icelanders and 296,496 relatives of genotyped…”
BackgroundInfluentialRare and common variants: twenty arguments
Gibson, G. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3118 · Cited by 1,278 · cited 2×
“Although AD is a condition with typical onset far beyond reproductive age, in general, deleterious alleles are more likely to be rare due to the laws of purifying selection (Gibson, 2011), so high impact alleles are unlikely to be detected by GWAS, which target common variants.”
BackgroundGenome-wide Analysis of Genetic Loci Associated With Alzheimer Disease
Seshadri, S. (2010) · JAMA · doi:10.1001/jama.2010.574 · Cited by 1,219
Uncovering the roles of rare variants in common disease through whole-genome sequencing
Cirulli, E. T., & Goldstein, D. B. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2779 · Cited by 1,136 · cited 1×
“Sequencing technologies have seen huge advances in accuracy, throughput, and cost effectiveness in recent years (Cirulli and Goldstein, 2010).”
BackgroundRare-Variant Association Analysis: Study Designs and Statistical Tests
Lee, S., Abecasis, G. R., Boehnke, M., & Lin, X. (2014) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2014.06.009 · Cited by 1,042 · cited 3×
“Despite a wealth of research over the following years, further linkage studies as well as numerous candidate gene investigations failed to find any further genetic risk loci for AD that were robust and replicable (Ertekin-Taner, 2010).”
BackgroundMethodAlzheimer's disease: early alterations in brain DNA methylation at ANK1, BIN1, RHBDF2 and other loci
De Jager, P. L., Srivastava, G., Lunnon, K., Burgess, J., Schalkwyk, L. C., Yu, L., Eaton, M. L., Keenan, B. T., Ernst, J., McCabe, C., et al. (2014) · Nature Neuroscience · doi:10.1038/nn.3786 · Cited by 956 · cited 2×
“However, with our current limited knowledge of the etiology of the disease, the appropriate targets and interventions remain unclear.”
National Institute of Diabetes and Digestive Kidney Diseases Inflammatory Bowel Disease Genetics Consortium (NIDDK IBDGC), Rivas, M. A., United Kingdom Inflammatory Bowel Disease Genetics Consortium, International Inflammatory Bowel Disease Genetics Consortium, Beaudoin, M., Gardet, A., Stevens, C., Sharma, Y., Zhang, C. K., Boucher, G., et al. (2011) · Nature Genetics · doi:10.1038/ng.952 · Cited by 771 · cited 1×
“Targeted sequencing, e.g., for loci identified by GWAS, is a cheaper alternative to whole genome or whole exome sequencing (WES), and has had some successes (Rivas et al., 2011).”
BackgroundMethylomic profiling implicates cortical deregulation of ANK1 in Alzheimer's disease
Lunnon, K., Smith, R., Hannon, E., De Jager, P. L., Srivastava, G., Volta, M., Troakes, C., Al-Sarraj, S., Burrage, J., Macdonald, R., et al. (2014) · Nature Neuroscience · doi:10.1038/nn.3782 · Cited by 574
An evaluation of statistical approaches to rare variant analysis in genetic association studies
Morris, A. P., & Zeggini, E. (2010) · Genetic Epidemiology · doi:10.1002/gepi.20450 · Cited by 481 · cited 1×
“The simplest of these are burden tests, but these do not account for variants in the same test unit having opposing directions of effects, which can cancel out any meaningful signals (Morris and Zeggini, 2010; Lee et al., 2014).”
BackgroundRare coding variants in the phospholipase D3 gene confer risk for Alzheimer’s disease
Cruchaga, C., Karch, C. M., Jin, S. C., Benitez, B. A., Cai, Y., Guerreiro, R., Harari, O., Norton, J., Budde, J., Bertelsen, S., et al. (2014) · Nature · doi:10.1038/nature12825 · Cited by 461 · cited 4×
“In search of further risk associated variants within the PLD3 gene, the group sequenced the gene’s coding region in 2363 cases and 2024 controls of European descent, as well as 130 cases and 172 controls of AA descent.”
BackgroundMethodInfluentialSelf-citationLoss of apolipoprotein E receptor LR11 in Alzheimer disease
Scherzer, C. R., Offe, K., Gearing, M., Rees, H. D., Fang, G., Heilman, C. J., Schaller, C., Bujo, H., Levey, A. I., & Lah, J. J. (2004) · Archives of Neurology · doi:10.1001/archneur.61.8.1200 · Cited by 316
Coding variants in TREM2 increase risk for Alzheimer's disease
Jin, S. C., Benitez, B. A., Karch, C. M., Cooper, B., Skorupa, T., Carrell, D., Norton, J. B., Hsu, S., Harari, O., Cai, Y., et al. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu277 · Cited by 314 · cited 2×
“Exome arrays offer a platform for genotyping exonic low frequency and rare variants in a chip based assay, bridging the gap between the sparse genotyping of GWAS and sequencing based study designs.”
BackgroundSelf-citationPottier, C., Hannequin, D., Coutant, S., Rovelet-Lecrux, A., Wallon, D., Rousseau, S., Legallic, S., Paquet, C., Bombois, S., Pariente, J., et al. (2012) · Molecular Psychiatry · doi:10.1038/mp.2012.15 · Cited by 305
Corneveaux, J. J., Myers, A. J., Allen, A. N., Pruzin, J. J., Ramirez, M., Engel, A., Nalls, M. A., Chen, K., Lee, W., Chewning, K., et al. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq221 · Cited by 237 · cited 1×
“…loci have been extensively replicated and shown to be linked to a variety of AD associated endophenotypes, giving extremely strong evidence for their genuine involvement in the etiology of the condition (Carrasquillo et al., 2010; Corneveaux et al., 2010; Jun et al., 2010; Seshadri et al., 2010).”
BackgroundKim, M., Suh, J., Romano, D., Truong, M. H., Mullin, K., Hooli, B., Norton, D., Tesco, G., Elliott, K., Wagner, S. L., et al. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp323 · Cited by 234
Replication of CLU, CR1, and PICALM Associations With Alzheimer Disease
Carrasquillo, M. M., Belbin, O., Hunter, T. A., Ma, L., Bisceglio, G. D., Zou, F., Crook, J. E., Pankratz, V. S., Dickson, D. W., Graff-Radford, N. R., et al. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.147 · Cited by 208 · cited 2×
“…loci have been extensively replicated and shown to be linked to a variety of AD associated endophenotypes, giving extremely strong evidence for their genuine involvement in the etiology of the condition (Carrasquillo et al., 2010; Corneveaux et al., 2010; Jun et al., 2010; Seshadri et al., 2010).”
BackgroundTREM2 is associated with the risk of Alzheimer's disease in Spanish population
Benitez, B. A., Cooper, B., Pastor, P., Jin, S.-C., Lorenzo, E., Cervantes, S., & Cruchaga, C. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.12.018 · Cited by 163 · cited 1×
“Using quantitative traits as endophenotypes has been shown to have increased power compared to standard designs, reducing the number of individuals to be sequenced substantially (Li et al., 2011; Benitez et al., 2013b).”
BackgroundSelf-citationTwo rare AKAP9 variants are associated with Alzheimer's disease in African Americans
Logue, M. W., Schu, M., Vardarajan, B. N., Farrell, J., Bennett, D. A., Buxbaum, J. D., Byrd, G. S., Ertekin‐Taner, N., Evans, D., Foroud, T., et al. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.06.010 · Cited by 136
The epigenetic landscape of Alzheimer's disease
Lord, J., & Cruchaga, C. (2014) · Nature Neuroscience · doi:10.1038/nn.3792 · Cited by 122 · cited 2×
“…association studies in the AD field, and together identified and replicated four loci where epigenetic alterations were associated with AD risk (De Jager et al., 2014; Lunnon et al., 2014), and it is likely more sites where epigenetic modifications relate to AD risk exist (Lord and Cruchaga, 2014).”
BackgroundSelf-citationApoE variant p.V236E is associated with markedly reduced risk of Alzheimer’s disease
Medway, C. W., Abdul-Hay, S., Mims, T., Ma, L., Bisceglio, G., Zou, F., Pankratz, S., Sando, S. B., Aasly, J. O., Barcikowska, M., et al. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-11 · Cited by 82 · cited 17×
“These variants were imputed in to an AD case control cohort (3550 AD, 8888 controls), and rs75932628 was the only variant to exceed the applied Bonferroni correction for multiple tests, other than those at the APOE locus (p = 3.42 × 10−10, odds ratio (OR) = 2.92 [95% confidence interval (CI) 2.09−4.09)].”
BackgroundMethodInfluentialAmyloid precursor protein (APP) A673T mutation in the elderly Finnish population
Kero, M., Paetau, A., Polvikoski, T., Tanskanen, M., Sulkava, R., Jansson, L., Myllykangas, L., & Tienari, P. J. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.09.017 · Cited by 72 · cited 2×
“This suggests the same loci may contribute to both early and late onset forms of the condition, and studies utilizing more extreme forms of the disease, which have increased power, may be informative about risk factors for the late onset, complex form of AD.”
BackgroundYu, J.-T., Jiang, T., Wang, Y.-L., Wang, H.-F., Zhang, W., Hu, N., Tan, L., Sun, L., Tan, M.-S., Zhu, X.-C., et al. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.10.075 · Cited by 68
Jiao, B., Liu, X., Tang, B., Hou, L., Zhou, L., Zhang, F., Zhou, Y., Guo, J., Yan, X., & Shen, L. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.04.025 · Cited by 66
Liu, Y.-W., He, Y.-H., Zhang, Y.-X., Cai, W.-W., Yang, L.-Q., Xu, L.-Y., & Kong, Q.-P. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.09.023 · Cited by 39
Ting, S. K. S., Chong, M.-S., Kandiah, N., Hameed, S., Tan, L., Au, W.-L., Prakash, K. M., Pavanni, R., Lee, T.-S., Foo, J.-N., et al. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.04.012 · Cited by 26
P4–329: A rare coding variant alters UNC5C function and predisposes to Alzheimer's disease
Hunkapiller, J., Wetzel, M., Bhangale, T., Maloney, J., Atwal, J., Ortmann, W., Tessier‐Lavigne, M., Goate, A., Behrens, T., Cruchaga, C., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.08.163 · Cited by 3
Self-citation
Cited by
Induced pluripotent stem cell technology: a decade of progress.
Shi, Y., Inoue, H., Wu, J. C., & Yamanaka, S. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.245 · Cited by 1,525
Santos, C. Y., Snyder, P. J., Wu, W., Zhang, M., Echeverria, A., & Alber, J. (2017) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2017.01.005 · Cited by 431
“Although many genetic risk factors for AD have been studied, a definitive genotype that causes (late onset) AD has not yet been identified [22].”
BackgroundNeuroinflammation in Alzheimer’s Disease
Onyango, I. G., Jauregui, G. V., Čarná, M., Bennett, J. P., & Stokin, G. B. (2021) · Biomedicines · doi:10.3390/biomedicines9050524 · Cited by 330
Genetic architecture of Alzheimer's disease
Neuner, S. M., TCW, J., & Goate, A. M. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104976 · Cited by 126
“Additional genes identified to harbor rare variants associated with AD risk include AKAP9, UNC5, and ADAM10, although the strength of these associations and the role of these genes in disease etiology remains less well-established (Lord et al., 2014; Del-Aguila et al., 2015).”
BackgroundTesi, N., van der Lee, S. J., Hulsman, M., Jansen, I. E., Stringa, N., van Schoor, N., Meijers-Heijboer, H., Huisman, M., Scheltens, P., Reinders, M. J. T., et al. (2019) · European Journal of Human Genetics · doi:10.1038/s41431-018-0273-5 · Cited by 65
Metadata
- Authors
- Lord, J., Lu, A. J., & Cruchaga, C.
- Venue
- Frontiers in Genetics
- Publisher
- Frontiers Media SA
- Published
- 2014-10-28
- Volume
- 5
- Pages
- 369-369
- ISSN
- 1664-8021 (ISSN-L)
- OpenAlex
- W2122843077
- Cited by
- 33
- References
- 31
- FWCI
- 3.50
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.